𝔖 Bobbio Scriptorium
✦   LIBER   ✦

80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis

✍ Scribed by J.S. Elborn; A. Sharma; Q. Deng; P. Koker


Book ID
118642991
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
51 KB
Volume
10
Category
Article
ISSN
1569-1993

No coin nor oath required. For personal study only.